Clinical Trials Browser

Phase 3 × atezolizumab × Breast × Clear all

NCT04873362 2026-03-04

Astefania

Phase 3 Active not recruiting

Breast Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Completed

190 enrolled 12 charts

Breast Neoplasms

NCT04148911 2025-12-26

EL1SSAR

Phase 3 Completed

184 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT03371017 2025-11-12

IMpassion132

Phase 3 Completed

595 enrolled 37 charts

Triple Negative Breast Neoplasms

NCT04740918 2025-08-08

KATE3

Phase 3 Terminated

96 enrolled 16 charts

Breast Neoplasms

NCT04732598 2025-02-05

AMBITION

Phase 3 Active not recruiting

Breast Neoplasms

NCT03726879 2024-11-05

IMpassion050

Phase 3 Completed

454 enrolled 28 charts

Breast Neoplasms

NCT03281954 2024-04-08

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT04177108 2024-03-27

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 3 Completed

242 enrolled 12 charts

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases, Triple Negative Breast Neoplasms

NCT03125902 2024-03-26

IMpassion131

Phase 3 Completed

653 enrolled 33 charts

Triple Negative Breast Neoplasms

NCT03595592 2024-03-06

APTneo

Phase 3 Active not recruiting

Invasive Breast Cancer

NCT03197935 2023-10-26

IMpassion031

Phase 3 Completed

333 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT02425891 2022-07-19

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Phase 3 Completed

902 enrolled 27 charts 1 FDA

Triple Negative Breast Neoplasms